Le Lézard
Classified in: Health
Subject: SVY

The cervical cancer therapeutics market will register a CAGR of nearly 7% by 2023


NEW YORK, May 22, 2019 /PRNewswire/ --

About this market

The advancements in diagnostics are one of the key factors expected to trigger the cervical cancer therapeutics market during the forecast period. Many medical devices companies are focusing on developing a revolutionary modular device for cervical cancer screening and diagnosis. This device has a dedicated computer with proprietary software, which helps in the accurate diagnosis of cancer. Therefore, such advances in diagnostic techniques of cervical cancers will not only help in identifying the correct stage of the carcinoma but also aid the oncologists in providing the right treatment to patients. Analysts have predicted that the cervical cancer therapeutics market will register a CAGR of nearly 7% by 2023.



Read the full report: https://www.reportlinker.com/p05777279/?utm_source=PRN



Market Overview

The growing popularity of targeted therapies

The growing R&D in this space and the positive clinical trials of late-stage molecules further support the growth prospects of the global cervical cancer treatment market during the forecast period.

Limited access to treatment

The lack of awareness and access to appropriate providers have been limiting the diagnosis and treatment of various cancers including cervical cancer.

For the detailed list of factors that will drive and challenge the growth of the cervical cancer therapeutics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Read the full report: https://www.reportlinker.com/p05777279/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 16:05
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...

at 16:05
Stevanato Group S.p.A. , a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first...

at 16:05
Bruker Corporation today announced it will report first quarter 2024 financial results before market opening on Thursday, May 2, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current...

at 16:05
Gilead Sciences, Inc. announced today its first quarter 2024 results of operations. "Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and...

at 16:05
DexCom, Inc. today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an...

at 16:05
Ironwood Pharmaceuticals, Inc. today announced it will host its first quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 9, 2024. Individuals interested in participating in the call should dial (888)...



News published on and distributed by: